These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 2543918)
1. Dopamine and memory function in Parkinson's disease. Mohr E; Fabbrini G; Williams J; Schlegel J; Cox C; Fedio P; Chase TN Mov Disord; 1989; 4(2):113-20. PubMed ID: 2543918 [TBL] [Abstract][Full Text] [Related]
2. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia. Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733 [TBL] [Abstract][Full Text] [Related]
3. Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease. Bravi D; Anderson JJ; Dagani F; Davis TL; Ferrari R; Gillespie M; Chase TN Mov Disord; 1992; 7(3):228-31. PubMed ID: 1620140 [TBL] [Abstract][Full Text] [Related]
4. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222 [TBL] [Abstract][Full Text] [Related]
5. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease. Rondot P; Ziegler M; Aymard N; Teinturier A Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765 [TBL] [Abstract][Full Text] [Related]
6. Off-period screaming accompanying motor fluctuations in Parkinson's disease. Steiger MJ; Quinn NP; Toone B; Marsden CD Mov Disord; 1991; 6(1):89-90. PubMed ID: 2005932 [No Abstract] [Full Text] [Related]
7. Recall and recognition memory in patients with Alzheimer's and Parkinson's diseases. Helkala EL; Laulumaa V; Soininen H; Riekkinen PJ Ann Neurol; 1988 Aug; 24(2):214-7. PubMed ID: 3178177 [TBL] [Abstract][Full Text] [Related]
8. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Lewis SJ; Slabosz A; Robbins TW; Barker RA; Owen AM Neuropsychologia; 2005; 43(6):823-32. PubMed ID: 15716155 [TBL] [Abstract][Full Text] [Related]
9. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations. Deleu D; Jacques M; Michotte Y; Ebinger G Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654 [TBL] [Abstract][Full Text] [Related]
15. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease. Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792 [TBL] [Abstract][Full Text] [Related]
16. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Metman LV; Hoff J; Mouradian MM; Chase TN Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216 [TBL] [Abstract][Full Text] [Related]
17. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604 [TBL] [Abstract][Full Text] [Related]
18. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Mouradian MM; Juncos JL; Fabbrini G; Chase TN Ann Neurol; 1987 Oct; 22(4):475-9. PubMed ID: 3435068 [TBL] [Abstract][Full Text] [Related]
19. [Usefulness of increasing the proportion of carbidopa to levodopa in the long-term treatment of Parkinson's disease]. Bermejo Pareja F; Martínez-Martín P Med Clin (Barc); 1984 Feb; 82(7):305-10. PubMed ID: 6717135 [No Abstract] [Full Text] [Related]
20. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]